355. Wintermark M, Reichhart M, Cuisenaire O, Maeder P, Thiran JP, Schnyder P, Bo- gousslavsky J, Meuli R. Comparison of admission perfusion computed tomo- graphy and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke. 2002; 33: 2025–2031.
356. Lev MH, CT versus MR for acute stroke imaging: is the „obvious” choice neces- sarily the correct one? AJNR Am J Neuroradiol. 2003; 24: 1930–1931.
357. Lev MH. CT versus MR for acute stroke imaging: is the „obvious” choice neces- sarily the correct one? AJNR Am J Neuroradiol. 2003; 24: 1930–1931.
358. Mukherjee P, Kang HC, Videen TO, McKinstry RC, Powers WJ, Derdeyn CP. Me- asurement of cerebral blood flow in chronic carotid occlusive disease: compa- rison of dynamic susceptibility contrast perfusion MR imaging with positron emission tomography. AJNR Am J Neuroradiol. 2003; 24: 862–871.
359. Coutts SB, Simon JE, Tomanek AI, Barber PA, Chan J, Hudon ME, Mitchell JR, Frayne R, Eliasziw M, Buchan AM, Demchuk AM. Reliability of assessing percen- tage of diffusion-perfusion mismatch. Stroke. 2003; 34: 1681–1683.
360. Ledezma CJ, Wintermark M. Multimodal CT in stroke imaging: new concepts.
Radiol Clin North Am. 2009; 47: 109–116.
361. Kudo K, Terae S, Katoh C, Oka M, Shiga T, Tamaki N, Miyasaka K. Quantitative cerebral blood flow measurement with dynamic perfusion CT using the vascu- lar-pixel elimination method: comparison with H2 (15) O positron emission to- mography. AJNR Am J Neuroradiol. 2003; 24: 419–426.
362. Kidwell CS, Saver JL, Starkman S, Duckwiler G, Jahan R, Vespa P, Villablanca JP, Liebeskind DS, Gobin YP, Vinuela F, Alger JR. Late secondary ischemic injury in patients receiving intraarterial thrombolysis. Ann Neurol. 2002; 52: 698–703.
363. Hunter GJ, Silvennoinen HM, Hamberg LM, Koroshetz WJ, Buonanno FS, Schwamm LH, Rordorf GA, Gonzalez RG. Whole-brain CT perfusion measure- ment of perfused cerebral blood volume in acute ischemic stroke: probability curve for regional infarction. Radiology. 2003; 227: 725–730.
364. Arakawa S, Wright PM, Koga M, Phan TG, Reutens DC, Lim I, Gunawan MR, Ma H, Perera N, Ly J, Zavala J, Fitt G, Donnan GA. Ischemic thresholds for gray and white matter: a diffusion and perfusion magnetic resonance study. Stroke. 2006;
37: 1211–1216.
365. Wintermark M, Flanders AE, Velthuis B, Meuli R, van Leeuwen M, Goldsher D, Pineda C, Serena J, van der Schaaf I, Waaijer A, Anderson J, Nesbit G, Gabriely I, Medina V, Quiles A, Pohlman S, Quist M, Schnyder P, Bogousslavsky J, Dillon WP, Pedraza S. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemi- spheric stroke. Stroke. 2006; 37: 979–985.
366. Koennecke HC. Challenging the concept of a dynamic penumbra in acute ische- mic stroke. Stroke. 2003; 34: 2434–2435.
367. Rosenthal ES, Schwamm LH, Roccatagliata L, Coutts SB, Demchuk AM, Scha- efer PW, Gonzalez RG, Hill MD, Halpern EF, Lev MH. Role of recanalization in acute stroke outcome: rationale for a CT angiogram-based „benefit of recanali- zation” model. AJNR Am J Neuroradiol. 2008; 29: 1471–1475.
368. Suarez J, Sunshine J, Tarr R, Zaidat O, Selman WR, Kernich C, Landis DM. Pre- dictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke.
1999; 30: 2094–2100.
369. Molina CA, Alexandrov AV, Demchuk AM, Saqqur M, Uchino K, Alvarez-Sabín J;
CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stro- ke. 2004; 35: 151–156.
370. Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, Barber PA, Par- sons M, Darby D, Davis S, Caplan LR, Edelman RE, Warach S. A three-item sca- le for the early prediction of stroke recovery. Lancet. 2001; 357: 2095–2099.
371. Nighoghossian N, Hermier M, Adeleine P, Derex L, Dugor JF, Philippeau F, Ylmaz H, Honnorat J, Dardel P, Berthezène Y, Froment JC, Trouillas P. Baseline magne- tic resonance imaging parameters and stroke outcome in patients treated by intravenous tissue plasminogen activator. Stroke. 2003; 34: 458–463.
372. Schellinger PD, Jansen O, Fiebach JB, Heiland S, Steiner T, Schwab S, Pohlers O, Ryssel H, Sartor K, Hacke W. Monitoring intravenous recombinant tissue pla- sminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke. 2000; 31: 1318–1328.
373. Albers GW. Expanding the window for thrombolytic therapy in acute stroke: the potential role of acute MRI for patient selection. Stroke. 1999; 30: 2230–2237.
374. Broderick JP, Lu M, Kothari R, Levine SR, Lyden PD, Haley EC, Brott TG, Grotta J, Tilley BC, Marler JR, Frankel M. Finding the most powerful measures of the ef- fectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stro- ke. 2000; 31: 2335–2341.
375. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Albers GW. Clinical and ra- diological correlates of reduced cerebral blood flow measured using magnetic resonance imaging. Arch Neurol. 2002; 59: 233–238.
376. Kloska SP, Nabavi DG, Gaus C, Nam EM, Klotz E, Ringelstein EB, Heindel W. Acu- te stroke assessment with CT: do we need multimodal evaluation? Radiology.
2004; 233: 79–86.
377. Nabavi DG, Kloska SP, Nam EM, Freund M, Gaus CG, Klotz E, Heindel W, Ringel- stein EB. MOSAIC: Multimodal Stroke Assessment Using Computed Tomogra- phy: novel diagnostic approach for the prediction of infarction size and clinical outcome. Stroke. 2002; 33: 2819–2826.
378. Baird AE, Benfield A, Schlaug G, Siewert B, Lövblad KO, Edelman RR, Warach S.
Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol. 1997; 41:
581–589.
379. Tong DC, Yenari MA, Albers GW, O'Brien M, Marks MP, Moseley ME. Correlation of perfusion- and diffusion-weighted MRI with NIHSS score in acute (<6.5 ho- ur) ischemic stroke. Neurology. 1998; 50: 864–870.
380. Barber PA, Darby DG, Desmond PM, Yang Q, Gerraty RP, Jolley D, Donnan GA, Tress BM, Davis SM. Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI. Neurology. 1998; 51: 418–426.
381. Beaulieu C, de Crespigny A, Tong DC, Moseley ME, Albers GW, Marks MP. Lon- gitudinal magnetic resonance imaging study of perfusion and diffusion in stro- ke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol. 1999; 46: 568–578.
382. Moseley ME, Bammer R. Diffusion-weighted magnetic resonance imaging. In:
Latchaw RE, Kucharczyk J, Moseley ME, eds. Imaging of the Nervous System:
Diagnostic and Therapeutic Applications. Philadelphia, Pa: Elsevier Mosby; 2005:
227–248.
383. Bammer R, Moseley ME. Perfusion magnetic resonance and the perfusion/dif- fusion mismatch in stroke. In: Latchaw RE, Kucharczyk J, Moseley ME, eds. Ima- ging of the Nervous System: Diagnostic and Therapeutic Applications.
Philadelphia, Pa: Elsevier Mosby; 2005: 303–322.
384. Parsons MW, Yang Q, Barber PA, Darby DG, Desmond PM, Gerraty RP, Tress BM, Davis SM. Perfusion magnetic resonance imaging maps in hyperacute stroke: re- lative cerebral blood flow most accurately identifies tissue destined to infarct.
Stroke. 2001; 32: 1581–1587.
385. Thijs VN, Adami A, Neumann-Haefelin T, Moseley ME, Marks MP, Albers GW. Re- lationship between severity of MR perfusion deficit and DWI lesion evolution.
Neurology. 2001; 57: 1205–1211.
386. Shih LC, Saver JL, Alger JR, Starkman S, Leary MC, Vinuela F, Duckwiler G, Go- bin YP, Jahan R, Villablanca JP, Vespa PM, Kidwell CS. Perfusion-weighted ma- gnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue. Stroke. 2003; 34: 1425–1430.
387. Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, Heiland S, Schwab S, Pohlers O, Ryssel H, Orakcioglu B, Sartor K, Hacke W. Stroke magne- tic resonance imaging within 6 hours after onset of hyperacute cerebral ische- mia. Ann Neurol. 2001; 49: 460–469.
388. Schaefer PW, Hunter GJ, He J, Hamberg LM, Sorensen AG, Schwamm LH, Koroshetz WJ, Gonzalez RG. Predicting cerebral ischemic infarct volume with diffusion and perfusion MR imaging. AJNR Am J Neuroradiol. 2002; 23:
1785–1794.
389. Kluytmans M, van Everdingen KJ, Kappelle LJ, Ramos LM, Viergever MA, van der Grond J. Prognostic value of perfusion- and diffusion-weighted MR imaging in first 3 days of stroke. Eur Radiol. 2000; 10: 1434–1441.
390. Wittsack HJ, Ritzl A, Fink GR, Wenserski F, Siebler M, Seitz RJ, Mödder U, Freund HJ. MR imaging in acute stroke: diffusion-weighted and perfusion imaging pa- rameters for predicting infarct size. Radiology. 2002; 222: 397–403.
391. Thomalla GJ, Kucinski T, Schoder V, Fiehler J, Knab R, Zeumer H, Weiller C, Röther J. Prediction of malignant middle cerebral artery infarction by early per- fusion- and diffusion-weighted magnetic resonance imaging. Stroke. 2003; 34:
1892–1899.
392. Fiehler J, von Bezold M, Kucinski T, Knab R, Eckert B, Wittkugel O, Zeumer H, Röther J. Cerebral blood flow predicts lesion growth in acute stroke patients.
Stroke. 2002; 33: 2421–2425.
393. Derex L, Hermier M, Adeleine P, Pialat JB, Wiart M, Berthezène Y, Froment JC, Trouillas P, Nighoghossian N. Influence of the site of arterial occlusion on mul- tiple baseline hemodynamic MRI parameters and post-thrombolytic recanaliza- tion in acute stroke. Neuroradiology. 2004; 46: 883–887.
394. Barber PA, Parsons MW, Desmond PM, Bennett DA, Donnan GA, Tress BM, Da- vis SM. The use of PWI and DWI measures in the design of „proof-of-concept”
stroke trials. J Neuroimaging. 2004; 14: 123–132.
395. Chalela JA, Kang DW, Luby M, Ezzeddine M, Latour LL, Todd JW, Dunn B, Wa- rach S. Early magnetic resonance imaging findings in patients receiving tissue plasminogen activator predict outcome: insights into the pathophysiology of acute stroke in the thrombolysis era. Ann Neurol. 2004; 55: 105–112.
50
Neurologia po Dyplomie • Tom 5 Nr 3 2010
CHOROBY NACZYNIOWE
Zalecenia dotyczące diagnostyki obrazowej w ostrym udarze niedokrwiennym mózgu 011-50_latchaw:kpd 2010-05-13 12:35 Page 50
51
Tom 5 Nr 3 2010 • Neurologia po Dyplomie
CHOROBY DEMIELINIZACYJNE
Poniżej przedstawiamy artykuł poglądowy omawiający stan aktualnej wiedzy o zapaleniu nerwów wzrokowych i rdzenia (neuromyelitis optica, NMO). Jest to jednostka chorobowa, o której ostatnio wiele można przeczytać w prasie naukowej, co wynika ze znacznego postępu, jaki dokonał się w ostatnich latach w zakresie diagnostyki i leczenia tej choroby. Autorzy amerykańscy w prezentowanej pracy omawiają patomechanizm NMO, obraz kliniczny oraz zasady rozpoznawania i leczenia.
Z punktu widzenia polskiego lekarza proces diagnostyczny i terapeutyczny NMO przebiega jednak nieco inaczej. Obecnie nie dysponujemy bowiem w Polsce możliwościami oznaczeń patognomonicznego dla NMO autoprzeciwciała przeciwko akwaporynie 4 (NMO IgG).
Szczególne znaczenie ma więc ocena kliniczna i neuroobrazowanie. Ponadto możliwości leczenia hamującego postęp NMO ograniczają się do klasycznej immunosupresji wobec braku dostępności rituksimabu.
Dr hab. n. med. Beata Zakrzewska-Pniewska Katedra i Klinika Neurologii
Warszawski Uniwersytet Medyczny
Neurologia po Dyplomie 2010; 5 (3): 51
051_zakrzewska:kpd 2010-05-13 12:36 Page 51
www.podyplomie.pl/neurologiapodyplomie
